SCHEMBL20189491

SCHEMBL20189491

COc1ccc(CN(Cc2ccc(OC)cc2)S(=O)(=O)CC(O)c2cc(F)ccc2F)cc1

nearest known ligand 0.58

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APLNR P35414 12/20 0.58
TAS2R14 Q9NYV8 7/20 0.48
BMP1 P13497 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20189985 1.00 APLNR (0.58) APLNRTAS2R14BMP1
SCHEMBL20189489 1.00 APLNR (0.58) APLNRTAS2R14BMP1
SCHEMBL18246361 0.91 APLNR (0.61) APLNRTAS2R14
SCHEMBL18245917 0.91 APLNR (0.61) APLNRTAS2R14
SCHEMBL18245914 0.91 APLNR (0.61) APLNRTAS2R14
SCHEMBL20190099 0.77 APLNR (0.48) APLNRTAS2R14
SCHEMBL20190581 0.77 APLNR (0.48) APLNRTAS2R14
SCHEMBL20190097 0.77 APLNR (0.48) APLNRTAS2R14
SCHEMBL22119648 0.76 APLNR (0.59) APLNRTAS2R14
SCHEMBL17613143 0.74 APLNR (0.47) APLNRTAS2R14BMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 US disclosed
EP-3541805-B1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC (US) 2020-10-14 EP disclosed
EP-3541805-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS Amgen Inc. (US) 2019-09-25 EP disclosed
WO-2018097945-A1 HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS AMGEN INC. (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R APLNR 13/4885TAS2R14 1828/4885BMP1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.